Mechanisms of leukemogenesis induced by bovine leukemia virus: prospects for novel anti-retroviral therapies in human
- 31k Downloads
In 1871, the observation of yellowish nodules in the enlarged spleen of a cow was considered to be the first reported case of bovine leukemia. The etiological agent of this lymphoproliferative disease, bovine leukemia virus (BLV), belongs to the deltaretrovirus genus which also includes the related human T-lymphotropic virus type 1 (HTLV-1). This review summarizes current knowledge of this viral system, which is important as a model for leukemogenesis. Recently, the BLV model has also cast light onto novel prospects for therapies of HTLV induced diseases, for which no satisfactory treatment exists so far.
KeywordsBovine Leukemia Virus Proviral Load Viral Expression Bovine Leukemia Virus Infection Persistent Lymphocytosis
List of abbreviations
avian leukosis virus
adaptator-related protein complex 3
activating transcriptor factor
bovine leukemia virus
calmodulin-depend kinase IV
complementary determining region
carboxyfluorescein diacetate succinimidyl ester
chronic lymphocytic leukemia
cyclic-AMP responsive element
CRE binding protein
cytotoxic T lymphocyte
enzootic bovine leukemia
farnesyl pyrophosphate synthetase
human immunodeficiency virus
human T-lymphotropic virus type 1
interferon regulatory factor
immunoreceptor tyrosine-based activation motif
immunoreceptor tyrosine-based inhibition motif
long terminal repeat
nuclear factor κB
major histocompatibility complex
peripheral blood mononuclear cell
proliferating cell nuclear antigen
protein kinase A
primate T-lymphotropic virus
receptor binding domain
rat embryo fibroblast
stromal cell-derived factor-1
spleen necrosis virus
tumor necrosis factor α
tax responsive element
upstream stimulating factor
The occurrence in cattle of a disease called "leukosis" was first reported by Leisering who described as early as in 1871 the presence of yellowish nodules in the enlarged spleen of a cow . In fact, spleen disruption consecutive to tumor formation is one of the most spectacular clinical manifestations of bovine leukemia. These tumors which result from a local accumulation of transformed B cells also infiltrate other tissues such as liver, heart, eye, skin, lung and lymph nodes (reviewed in [2, 3, 4, 5]). Two types of bovine leukemia can be dissociated on the basis of their epidemiology: Enzootic Bovine Leukosis (EBL), a disease caused by a retrovirus called BLV (Bovine Leukemia Virus), and sporadic bovine leukosis which is not transmissible. Besides the lethal form of BLV-induced leukemia, persistent lymphocytosis (PL) is characterized by a permanent and relatively stable increase in the number of B lymphocytes in the peripheral blood. The PL stage, which affects approximately one third of infected animals, is considered to be a benign form of the disease resulting from the accumulation of untransformed B lymphocytes. Finally, viral infection is asymptomatic in the majority of BLV-infected animals; in these settings, fewer than 1 % of peripheral blood cells in animals are found to be infected by virus.
BLV is transmitted horizontally through the transfer of infected cells via direct contact, through milk and possibly by insect bites . However, iatrogenic procedures like dehorning, ear tattooing and, any use of infected needles contribute significantly to viral spread [7, 8, 9, 10]. BLV is nowadays highly prevalent in several regions of the world (e.g. United States) and induces major economical losses in cattle production and export [11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21]. For instance, the loss to the dairy industry due to BLV in 2003 was estimated annually at $525 million. In contrast, Denmark was the first country where the virus has been eradicated through the systematic destruction of infected herds. It is remarkable that the identification of infected animals was performed on basis of peripheral blood cell counts without the availability of specific serological tests (Bendixen's key) . BLV is now almost completely eradicated from the European Union after many years of culling infected animals. Since these costly eradication programs are only possible in regions where viral prevalence is low, other strategies have also been considered including isolation of infected animals, passive immunization with colostrum, vaccination with viral proteins or attenuated strains, as well as some other exotic approaches ([5, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34] and references therein). None of these latter methods currently achieve the optimal combination of efficiency, economy and safety.
Domestic cattle are the natural hosts for BLV. The existence of wild reservoirs remains controversial, but convincing evidence indicates that BLV indeed persists in water buffaloes [35, 36, 37]. Experimental transmissions of BLV have been reported in many species including rabbits [38, 39, 40], rats [41, 42], chickens , pigs , goats  and sheep [9, 46, 47, 48]. However, only sheep consistently develop leukemia whereas rabbits present immune dysfunctions (but no tumors, in a finding different from rabbits inoculated with HTLV ). Rare cases of experimental transformation were reported in goats, rats and even chicken. Despite successful infection of a series of cell lines in vitro [50, 51, 52, 53], BLV does not persistently infects cat, dog, monkey or human although viral-specific seroconversion might occur in these species. Epidemiological studies have shown that consumption of raw milk from BLV-infected cattle does not increase the frequency of leukemia in man (reviewed in [54, 55, 56]). Therefore, it is unlikely that BLV infects, replicates and induces cancer in humans, although this cannot be formally excluded . Instead, four BLV related retroviruses have been isolated in man: Human T-lymphotropic viruses type 1 to 4 (HTLV-1 to -4) [58, 59, 60]. Among these, HTLV-1 infects about 20 million people worldwide, a fraction of whom (about 2–3 %) progress to develop acute T-cell leukemia (ATL) or HTLV-Associated Myelopathy/Tropical Spastic Paraparesis (HAM/TSP), a neuroinflammatory disease of the central nervous system.
2. The BLV genome
In addition to the structural gag, pol and env genes required for the synthesis of the viral particle, the BLV genome contains a X region located between the envelope and the 3' long terminal repeat [61, 62, 63], as also observed in other deltaretroviruses [58, 60]. Phylogenetic comparisons of different strains, using the pol gene as a reference, indicate that BLV and primate T-lymphotropic viruses (PTLV) sequences differ by 42 % ; thus BLV forms a distinct clade amongst retroviruses. Within the BLV subgroup, the sequence divergence was below 6% in pol and env indicating a high degree of conservation among different geographical strains [24, 25, 65, 66, 67]. Although the reasons are unknown, this genomic stability might result from a higher fidelity of reverse transcription or from strict replication constraints.
The genomic RNA
The 3' end of the genomic RNA also contains a highly structured region (RxRE), which is needed to mediate RNA transport from the nucleus to the cytoplasm (see paragraph on post-transcriptional regulation by Rex). After transcription and nuclear export, the genomic RNA can either be directly translated to yield the Pr145gag-pol precursor or incorporated into a budding viral particle.
The long terminal repeat
The genomic RNA is a 9 kb ribonucleic acid molecule flanked by R regions of the long terminal repeats (Figure 2). In addition to this transcript, a series of other RNAs can be synthesized in infected cells with two major species of 5.1 kb (the env RNA) and 2.1 kb (tax/rex) and several less abundant RNAs coding for R3 and G4 [79, 80]. All these transcripts initiate at the boundary between U3 and R (the CAP site) and terminate with polyadelylation at the end of R in the 3' LTR. The U3 region contains the canonical promoter "CAT" box (CCAACT at coordinates -97 to -92) and "TATA" boxes (GATAAAT between -44 and -38). Another series of sites mainly located in the U3 region of the 5' LTR regulate viral transcription [81, 82].
A key regulatory element of the LTR is a triplicate copy of a 21 bp sequence called TxRE harboring in the middle of the sequence an almost perfectly conserved cyclic-AMP responsive element (CRE) with an overlapping E box motif. Only two of these TxREs are required for infectivity and pathogenicity in sheep . In gel retardation assays with primary B lymphocyte lysates, the TxRE element interacts with the CREB, ATF-1 and ATF-2 transcription factors and the amount of protein-DNA complex correlates with the level of viral expression [84, 85]. The CREB/ATF transcription factors regulate LTR-directed transcription when activated by two cellular protein kinases (i.e. PKA and CaMKIV). The 21 bp enhancer is also a target of the Tax protein, a viral transcriptional activator which increases the binding of CREB to DNA . In fact, the internal CRE-like sequences (AGACGTCA, TGACG GCA, TGACCTCA), a property which is shared by the related HTLV-1 LTR , are close to but different from the consensus "TGACGTCA". Restoring a perfect CRE sequence into the 21 bp sequences increases the BLV LTR promoter activity in reporter assays, but interferes with viral replication in vivo . Indeed, the proviral loads are drastically reduced in sheep infected with a virus harboring perfect consensus CRE elements (see section 4, below). Another regulatory process is exerted by E-box motifs which overlap the CRE elements and repress basal LTR-driven gene expression .
Although the 21 bp enhancer is a major regulator of viral expression, other U3 elements also modulate LTR-directed transcription. Among them, a NF-κB-related site located between the proximal and middle 21 bp enhancers, binds in vitro to several members of the kappa B family of proteins including p49, p50 and p65 and confers further transcriptional activation [90, 91]. Another motif, located just 5' to the proximal 21 bp, is required for responsiveness of the LTR promoter to glucocorticoids [92, 93]. A PUbox located at coordinates -95/-84 bp specifically interacts with PU.1 and the related Ets transcription factor Spi-B . Mutations within this element decrease LTR-driven basal gene expression but does not impair responsiveness to Tax. An E-box motif (5'-CACGTG-3') located downstream of the transcription start site binds the basic helix-loop-helix transcription factors USF1 and USF2 and regulates the LTR promoter . In addition to these U3 elements, viral expression is regulated also by sequences in the R region . Finally, an interferon regulatory factor binding site in U5 interacts with IRF-1 and IRF-2 and stimulates basal expression in the absence of Tax . Viral transcription thus appears to be regulated by numerous sites distributed throughout the 5' LTR.
Viral transcription is regulated at a separate level by epigenetic modifications such as acetylation of histone molecules and DNA methylation. Indeed, cultivation of peripheral blood mononuclear cells (PBMCs) from BLV-infected animals in the presence of histone deacetylase (HDAC) inhibitors significantly increases viral expression . A close correlation links the level of histone acetylation and transcriptional activation of the LTR . HDAC inhibitors synergistically enhance transactivation of the LTR by Tax in a CRE-dependent manner . Trichostatin A increases the occupancy of the CRE elements by CREB/ATF as shown by chromatin immunoprecipitation assays.
DNA methylation could be another means for regulating LTR-transcription. Indeed, in vitro methylation of the LTR by CpG methyltransferase SssI reduces LTR activity in luciferase reporter assays . However, only minimal modifications of CpG methylation were detected at all stages examined in BLV-infected cattle and sheep. Further experiments are therefore required to clarify the role of methylation in LTR activity, as has been described in the HTLV system .
Finally, viral expression is also regulated at the post-transcriptional level by a viral protein called Rex which interacts with RNA sequences in the 3'LTR located between the AATAAA signal and the polyadenylation site . This region is able to fold into a stable RNA hairpin structure and brings the two transcription termination signals together. Rex binding is required for the nuclear to cytoplasmic export of unspliced and singly spliced, but not for multiply spliced, BLV transcripts.
The gag and protease genes
The gag gene codes for the Pr44gag precursor, a polypeptide subsequently cleaved into the major non-glycosylated proteins of the viral particle (p15, p24 and p12) (Figure 2) [70, 102, 103, 104, 105, 106]. The matrix (MA) protein p15 (109 aa) which corresponds to the NH2-terminal end of the gag precursor is a myristylated and phosphorylated polypeptide. MA proteins bind the genomic viral RNA but also interact with the lipid bilayer of the viral membrane. Structurally, MA contains four principal helices that are joined by short loops . The matrix protein can be further proteolytically processed to generate three fragments: p10, a seven amino acids product, and p4 . p10, which is also myristylated, results from the amino-terminal cleavage of MA.
The p12 nucleocapsid (NC) is a proline-rich 69 aa protein that is tightly bound to the packaged genomic RNA [71, 108]. In the presence of Zn2+, NC interacts with single-stranded nucleic acids with an affinity in the nanomolar range .
p24, a neutral and moderately hydrophobic protein, is the major constituent of the capsid (CA) of BLV virions. The CA protein appears to be a major target for the host immune response with high antibody titers found in the sera of infected animals and two defined regions of p24 being recognized by specific T lymphocytes [110, 111]. One of the T-cell epitopes overlaps with a domain highly conserved among retroviruses, the major homology region (MHR), which is required for viral infectivity in vivo . Based on the use of a monoclonal antibody directed against BLV p24, a common epitope was found to be shared with HTLV CA [113, 114]. Interestingly, this cross-reactivity between the capsid antigens of BLV and HTLV-1 suggests an evolutionary relationship between the two viruses. Of note, an immunological cross-reaction is also observed between the BLV and the feline leukemia virus (FeLV) nucleocapsid NC proteins .
Different BLV Gag proteins (MA, CA and NC) are derived from the proteolytic cleavage of the Pr44gag precursor. This post-translational maturation is carried out by the viral protease p14 which is encoded by a region located between the gag and the pol genes. p14 is synthesized from a gag-protease precursor (pr66gag-prt) via a frameshift suppression of the gag termination codon by a lysine-specific tRNA . The pr66gag-prt precursor localizes at the surface of polarized cells . The p14 protein, which assembles into dimers, belongs to the aspartyl proteinase group and can be inhibited by pepstatin A . Despite their evolutionary relationship, the BLV and HTLV proteases harbor marked specificities in cleavage site recognition .
Overexpression of the Gag polyprotein in mammalian cells generates virus-like particles (VLPs). VLPs production depends on the PPPY motif located in the MA domain and on the amino-terminal glycine involved in Gag myristylation. The PPPY sequence functions as a late domain and plays a role in budding of the viral particle [120, 121]
The pol gene
The pol gene is translated via a frameshift mechanism, as a 145-kDa precursor (852 aa) . Pr145 contains all of the tryptic peptides of the gag-protease precursor and thus represents an elongation product of pr66gag-prt. The pol gene encodes a 80 kDa reverse transcriptase (RT), a RNA-dependent DNA polymerase which is preferentially active in the presence of Mg2+ [122, 123]. In fact, the enzyme shows a preference for Mg2+ over Mn2+ in both its DNA polymerase and RNase H activities . BLV RT is relatively resistant to nucleoside triphosphate analogues known to be potent inhibitors of human immunodeficiency virus (HIV-1) reverse transcriptase. Bacterially produced BLV RT is enzymatically active as a monomer even after binding a DNA substrate . Amazingly, sera from some leukemic cattle contain antibodies that inhibit reverse transcriptase activity in vitro.
The synthesis of the minus strand DNA by RT begins at the primer binding site for tRNA pro in the genomic template RNA located just 2 bp downstream of U5. BLV reverse transcriptase exhibits a higher fidelity than that from spleen necrosis virus: only 1.2 × 10-5 base mutations (versus 4.8 × 10-6 for SNV) occur per round of replication . In fact, BLV RT shows a fidelity of misinsertion better than that of HIV-1 RT but a similar degree of mispair elongation (i.e. the ability to extend these 3' end mispairs) .
After infection of permissive cells, two species of covalently closed circular DNA molecules, harboring one or two LTR copies, are synthesized after reverse transcription [127, 128]. Unintegrated viral DNA molecules are abundant in asymptomatic and PL cattle but they appear to be absent during the tumor phase . Insertion of the double-stranded DNA, also known as the provirus, is directed by the virally encoded integrase IN [130, 131]. During DNA rearrangement, the integrase recognition sequence includes the 3' end of the U5 LTR region . Once inserted at random sites into the host genome, the provirus is flanked by direct repeats of cellular DNA .
The envelope gene
The sequences coding for the BLV envelope partially overlap in a different frame the 3' end of pol by 51 nucleotides [62, 133, 134]. The envelope gene is transcribed as a 5.1 kb mRNA coding for the pr72env precursor [70, 80, 103, 105, 106, 135]. The BLV and HTLV envelopes show 36 % of identities in their amino acid sequence. The BLV pr72env precursor is cleaved into two subunits by subtilisin/kesin-like convertases such as furin . The resulting products, the extracellular gp51 (SU) and the transmembrane gp30 (TM) proteins are glycosylated polypeptides [137, 138, 139, 140]. SU and TM associate through disulfide bonds, conferring a relatively stable complex .
Interestingly, the pr72env precursor polyprotein is not evenly distributed but concentrates predominantly in only one daughter cell . This mechanism might account for the absence of viral antigens in a proportion of the cell progeny and permit persistence of the virus (see hypothetical model in section 6, below)
In contrast to TM which is very poorly immunogenic, the extracellular SU induces massive expression of specific antibodies in infected animals, a property useful for diagnostics and vaccine development. Some monoclonal antibodies (F, G and H) directed towards conformational epitopes of SU exhibit neutralizing activities [137, 142, 143]. None of the known viral strains are simultaneously lacking F, G and H reactivities, suggesting that loss of these three epitopes probably means loss of infectivity. In addition, rabbit antisera raised against peptides 39–48, 78–92, 144–157 and 177–192 neutralize VSV/BLV pseudotypes in vitro, indicating that these epitopes are also implicated in viral infectivity [144, 145]. Interestingly, residues 144 to 157 of SU correspond to the region in the HTLV-1 envelope glycoprotein which is also involved in neutralization. Cell fusion, i.e. syncytium formation, is inhibited by sera directed towards peptides 64–73, 98–117 and 177–192. This last sequence (in particular residues P177 and D178 of SU), which stimulates proliferation of lymphocytes isolated from infected cows, is a T-helper epitope. Finally, CD8-dependent cytotoxic activity is associated with peptides 121–140, 131–150 , or 24–31 [147, 148].
In silico modeling indicates that SU glycoprotein oligomerizes as a trimer, in which the putative receptor binding domain (RBD) corresponds to the most efficient neutralizing epitopes [141, 143, 149]. It should be mentioned here that this cellular receptor for BLV is still unknown, in contrast to those of HTLV-1 (i.e. glut-1 and neuropilin-1) [150, 151]. Although a candidate molecule able to interact with SU has been identified , it later appeared that this protein corresponds to the δ subunit of adaptor-related protein complex AP3 involved in intracellular vesicle transport .
Since cell-free infection by BLV appears to be very inefficient most probably due to virion instability, the main route of transmission is thought to occur through fusion between an infected cell harboring envelope proteins at its surface and a new target lymphocyte [154, 155]. The TM transmembrane protein is a key factor during this process which uses a fusion peptide that is able to destabilize the cell membrane through its oblique insertion into the lipid bilayer  triggered by the dynamic structural reorganization of the TM aminoterminal end. Two domains of SU, peptide 19–27 which adopts an amphiphilic structure  and region 39–103 , are also required for efficient cell fusion. Finally, a region of SU localized between residues 104–123 interacts with zinc and affects viral fusion as well as infectivity in vivo .
In addition to its role in cell fusion, the TM protein is involved in signal transduction via immunoreceptor tyrosine-based activation (ITAM) motifs present in the cytoplasmic tail [159, 160]. The critical site of the ITAMs consists of a YXXL sequence (where X represents a variable residue). Similar ITAM motifs are also found in Ig alpha protein of the B cell antigen receptor complex and can be recognized by SH2 domains of signaling proteins. When fused to the CD8 molecule, the TM ITAM motifs are able to transduce signals through the cell membrane after stimulation with an anti-CD8 antibody. These motifs are also important for incorporation of envelope proteins into the virion  and are required for infectivity in vivo .
Using a similar approach of chimeric proteins, the TM cytoplasmic domain has been found to be involved in the modulation of intracellular envelope trafficking . Replacement of two proximal dileucine motifs with alanines increases the surface display of CD8-TM chimeric proteins indicating that these motifs downmodulate cell surface expression of envelope proteins .
Besides ITAMs and dileucine motifs, the TM cytoplasmic tail has homology with immunoreceptor tyrosine-based inhibition motifs (ITIMs), which are homologous to B-cell receptor (BCR) and inhibitory co-receptor motifs; however, the functional relevance of these sites remains unclear . The TM cytoplasmic tail also contains typical proline-rich motifs (PXXP) which correspond to SH3 recognition sites. These motifs are not required for viral infectivity but are important for the maintenance of high viral load in vivo .
Finally, BLV TM interacts with phosphatase SHP-1 that associates with FcγRIIB and acts as a critical negative regulator of BCR signaling . This association suggests the hypothesis that TM may act as a decoy to sequester SHP-1, resulting in up-regulation of BCR signaling.
The R3 and G4 open reading frames
G4 is likely implicated in cell transformation because its ectopic expression in primary rat embryo fibroblasts induces their immortalization . Furthermore, G4 interacts with farnesyl pyrophosphate synthetase (FPPS), a protein involved in the mevalonate/squalene pathway and in synthesis of FPP, a substrate required for prenylation of Ras . HTLV-1 p13II also specifically interacts with FPPS and colocalizes with G4 in mitochondria, indicating that both accessory proteins exert related functions.
R3 and G4 are dispensable for infectivity in vivo but the integrity of these genes is essential to allow efficient propagation inside the host [83, 170, 172]. Furthermore, recombinant viruses deleted in R3 and G4 are very poorly pathogenic in sheep with a single exception out of 20 infected animals having been observed after more than 7 years of latency (Florins et al, manuscript in preparation).
Almost 3 decades ago, a 18 kDa protein was identified by in vitro translation of RNA isolated from virions . This 18 kDa product was antigenically unrelated to the viral structural proteins and originated from the 3' end of the provirus. Later, it was discovered that this viral protein resulted from the translation of the rex orf [173, 174]. The rex sequences are well conserved amongst various BLV isolates with less than 5% variation .
The Rex protein has a punctate nuclear localization, associates with nuclear pores and harbors a nuclear export signal (Figure 3) [24, 25, 176]. Rex contains a central leucine-rich activation domain and amino-terminal arginine-rich motifs required for RNA-binding and nuclear localization.
Rex is required for the accumulation of genomic and singly-spliced env RNAs . This trans-acting regulation of viral mRNA processing requires a 250-nucleotide region located between the AATAAA signal and the polyadenylation site in the 3'LTR. The Rex proteins of HTLV-1 and BLV are interchangeable for purposes of post-transcriptional regulation .
The messenger RNA coding for BLV Rex results from the excision of two introns: one is located between the major splice site at nucleotide 305 (according to ) and an acceptor at the end of the pol gene (position 4649), and the other spans residues 4871 to 7247. This complex double-splicing mechanism yields a 2.1 kb molecule coding not only for Rex, but also for the Tax protein [80, 178]. In vitro, the tax/rex message which is not itself regulated by Rex , is present in the cytoplasm during an early phase preceding the accumulation of the other mRNA coding for the structural proteins . Finally, the expression of the tax/rex mRNA but not other viral RNAs, is maintained in vivo at late phases of leukemia or lymphosarcoma .
The Tax transactivator
The other protein encoded by the 2.1 kb multiply-spliced mRNA is Tax, a transcriptional activator of viral expression. Initiation of tax translation occurs at a methionine residue located just upstream of the pol stop codon [80, 181]. The Tax orf is the largest of the X region located between the env gene and the 3' LTR (Figure 2). The Tax protein is a target of the host immune response with T and B epitopes corresponding to regions 110–130/131–150 and 261–280, respectively .
The importance of tax has been suggested by the absence of deletions affecting this orf during the process of leukemogenesis [183, 184]. However, some proviruses harboring deletions in the central portion of the genome do not contain the second exon required for initiation of Tax. These deletants are thus unable to express Tax, although all of them could at least in theory, express G4. It is still possible that a Tax protein is synthesized via other splicing processes or is provided in trans by other infected cells . Besides these speculations, it is clear that the integrity of the tax gene is essential for viral infectivity in vivo [83, 186].
The Tax protein is rich in proline (13 %) and leucine (16 %) residues and has a relatively short half life (5 to 6 hours) . It is mainly localized in the nucleus, although significant amounts are also present in the cytosol [187, 188] (Figure 3). Tax is post-translationally modified by phosphorylation of two serine residues (106 and 293) and exhibits at least three forms with measured isoelectric points of 6.05, 6.25 and 6.45 [188, 188, 189]. Although its calculated molecular weight is 34,328, Tax migrates as a 34–38 kDa product, probably due to its phosphorylation.
The first identified function of Tax is activation of viral transcription [190, 191]. This mechanism of transactivation by Tax requires interaction with cellular transcription factors, like CREB, which bind to the 21 bp enhancer elements in the 5'LTR. A very narrow range of variations is compatible with full transactivation activity, suggesting that the present molecular structure of Tax results from heavy evolutionary constraints [192, 193, 175]. In addition to the main phosphorylation sites at serines 106 and 293, Tax is structurally characterized by the presence of an aminoterminal zinc finger and by a leucine-rich activation domain located between residues 157 and 197 [188, 194]. Deletion of the activation domain or substitutions of amino acids involved in the zinc finger completely abolish Tax's transactivation activity. The region between amino acids 245 and 265 of the Tax protein reduces LTR-directed transactivation . A Tax mutant within this region, which also harbors increased c-fos transactivation activity , does not propagate virus at higher rates in vivo . PBMCs infected with the Tax mutant virus are less prone to undergo intrinsic apoptosis ex vivo, a process which involves the Bcl-xl protein .
Besides its function as a transcriptional activator, Tax induces immortalization of primary rat embryo fibroblasts (REF) [170, 194, 199]. In addition, Tax cooperates with the Ha-ras oncogene to induce full transformation of cells that form tumors when injected into nude mice, a property shared with G4 (see above). These activities which are also seen with the Myc oncogene, underline the immortalizing potential of Tax. Tax is thus not strictly an oncogene because it does not have a cellular counterpart but behaves as such in a way similar to the well defined Myc protein. The oncogenic potential of Tax can be dissociated from its transcriptional activation potential by specific mutations. Alterations of the zinc finger yield transactivation-deficient but transformation-competent mutants . In contrast, the main phosphorylation sites are dispensable for transactivation but are required for oncogenicity in the REF system (see section 4) [200, 201].
The mechanisms by which Tax induces transformation are still largely unknown. Expression of Tax in primary ovine B lymphocytes, which are dependent on CD154 and interleukin-4, impacts cell proliferation and survival leading to cytokine independent growth . This immortalization process correlates with increased Bcl-2 protein levels, nuclear accumulation of NFκB and a series of intracellular pathways which remain to be characterized . Tax also inhibits base-excision DNA repair of oxidative damage, potentially increasing the accumulation of ambient mutations in cellular DNA .
To further understand its mechanisms of action, Tax-associated cellular interacting proteins have been identified using a two-hybrid approach. For example, Tax directly binds to tristetraprolin (TTP), a post-transcriptional modulator of TNFα expression . Tax promotes nuclear accumulation of TTP and restores TNFα expression by inhibiting TTP. Interestingly, this process is shared by the HTLV-1 Tax protein, supporting a key role of this process during cell transformation. Another Tax-interacting protein is MSX2, a general repressor of gene expression, including LTR-dependent transcription . MSX2 repression can be counteracted by overexpression of the CREB2 and RAP74 transcription factors. A third Tax-binding protein is the G protein β subunit . In conditional Tax-1-expressing transformed T-lymphocytes, Tax expression correlates with activation of the SDF-1/CXCR4 pathway.
3. BLV infects B lymphocytes
Although it has been reported that BLV could persist in other cell types [207, 208, 209, 210, 211, 212, 213, 214], it seems clear that the major target of the virus is a B lymphocyte which expresses surface immunoglobulin M [215, 216, 217, 218, 219]. In addition to B lymphocytes, BLV also persists in cells of the monocyte/macrophage lineage. Immunoglobulin γ heavy chains are frequently found on lymphoma cells from cattle, consistently with a mature B cell phenotype [219, 220]. Sequencing of VDJ rearrangements in IgM-secreting B lymphocytes from a BLV-infected cow indicates that IgM antibodies are functional, exhibit polyspecific reactivity and contain exceptionally long CDR3H . Such long HCDR3s, which are also often found in poor outcome chronic lymphocytic leukemia patients (B-CLL), characterize antibodies directed towards negatively charged autoantigens (e.g., DNA) .
In addition to these markers pertaining to B lymphocytes, infected cells frequently co-express the CD5 molecule. B cell lymphocytosis essentially results from an increased proliferation of circulating CD5+ B lymphocytes associated with a lower but significant increase of the CD5- B cell population [223, 224, 225, 226]. Although the provirus has been detected in both CD5+ and CD5- B lymphocytes from infected animals, lymphosarcoma cells appear to exhibit mainly, but not exclusively, the CD5+ B phenotype . CD5 physically associates with the BCR in B lymphocytes from normal but not from PL cattle . BCR crosslinking decreases apoptosis of CD5+ B cells from uninfected animals but does not impact on those of PL cattle in which CD5 is already dissociated from the BCR. In contrast to CD5-negative B cells, BCR in B cells of PL cattle resists movement into lipid rafts upon stimulation and is only weakly internalized . Disruption of CD5-BCR interactions and subsequent decreased apoptosis in antigenically stimulated B cells may thus be a mechanism of BLV-induced PL.
In contrast, the CD5 molecule is often not expressed on tumor cells from BLV-infected sheep [229, 230]. Favored growth of CD5 positive cells might result from a difference in susceptibility to apoptosis . Another marker, the CD11b integrin molecule better defines the leukemic cell populations, although the virus infects both CD11b+ and CD11b- cells. These two populations also exhibit marked differences in cell kinetics (see section 6). In addition, the BLV-target cells express the IL-2 receptor (CD25) and the major histocompatibility class II complex or a related molecule previously called the tumor associated antigen (TAA) [219, 220, 232, 233, 234]. This antigen is probably the most frequently expressed protein at the surface of BLV target cells. Monoclonal antibodies recognizing this molecule inhibit the growth of BLV-infected lymphoid cells and induce tumor regression. Molecular cloning of cDNAs corresponding to bovine MHC II (BoLA) indicated that the TAA is closely related, but not identical to BoLA-DR. Of note, B lymphocytes from PL cows express increased spontaneous expression of the MHC class II molecule .
To summarize, it appears that the target cell for BLV is MHCII+ surface IgM+, CD5+ and CD11b+ with some fluctuations for the three latter markers at late stages of the disease. In contrast, HTLV-1 clearly infects other cell types CD4+ and CD8+ T lymphocytes [236, 237], underscoring a major difference between the two viral systems.
4. Viral genetic determinants required for infection and pathogenesis
Although sheep are not natural hosts for BLV, studying infection and pathogenesis in this model might be informative for understanding pathogenesis pertaining to other deltaretroviruses. To circumvent the problem of genomic RNA instability, infectious proviruses were cloned and injected into sheep or calves [30, 83, 238, 239]. Hence, infection of sheep with proviral clone 344 leads to tumor or leukemia after a mean latency period of 33 months . Since the BLV provirus can be re-amplified from the tumor cells, the three conditions required to fulfill Koch's postulate are demonstrated (i.e. the cloning of the virus, the analysis of its pathogenicity, and its re-isolation from the lesions), clearly establishing viral causality in leukemia/lymphoma.
Among other isolates, clone 395 is deficient for infectivity in vivo, due to the presence of a E-to-K mutation at codon 303 of the Tax protein [83, 184, 186]. In cell culture, transfection of provirus 395 yields reduced levels of Tax activity (~ 10 % of wild-type) although the amount of major capsid protein p24 expressed inside the cells and in the supernatant remains unaffected. Adequate levels of transactivation are required for infectivity in vivo supporting the notion that tax is an essential gene.
Summary of unexpected conclusions deduced from the BLV/sheep model
Fusion-deficient viruses can propagate at wild type levels
A transformation-deficient tax mutant is leukemogenic in sheep
A large region between the env and R3 genes is dispensable for infectivity and viral spread
Deletion of R3/G4 affects but does not abrogate pathogenicity
Increasing LTR promoter activity decreases viral spread
The BLV 344/sheep system has been instrumental for unraveling determinants of the viral replication cycle. Binding of the viral envelope complex to the target cell membrane leads to a process of fusion, allowing subsequent viral entry. The fusion mechanism can be reproduced in vitro by co-cultivation of fibroblasts or lymphocytes expressing Env proteins at their surface and target cells like CC81, leading to polykaryocytosis . The fusion process is mediated by the oblique insertion of the TM aminoterminal peptide into the lipid bilayer of the cell membrane. Forcing the peptide to adopt a parallel orientation by mutation abrogates fusion in cell culture and infectivity in vivo . In contrast, replacement of the peptide by the corresponding residues derived from SIV (simian immunodeficiency virus) yields a fully fusion-competent envelope. However, a virus carrying this mutation lacks infectivity, suggesting that additional constraints are operative in vivo. What is even more surprising is that TM mutants (i.e. A60V and A64S) that are deficient for cell fusion in vitro nevertheless support viral infectivity in vivo . And, very unexpectedly, these mutant viruses can propagate at wild-type levels and are pathogenic in sheep (see Table 1). Since the A60V and A64S mutants are also impaired for SU/TM interaction, it seems that integrity of the envelope complex is not strictly required in vivo. If the cell fusion processes in vitro and in vivo are indeed impaired equally by these mutations, then the findings offer the unexpected suggestion that BLV replicates by mitotic division of the infected cell rather than by de novo envelope-cell receptor mediated infectious cycle.
The tax gene is assumed to be a major factor required for viral replication and pathogenesis. Tax activates LTR-directed transcription and immortalizes primary cells in culture [190, 191, 199, 202, 243]. The two activities of Tax can be dissociated; for example, mutations in the zinc finger abrogate transactivation without altering immortalization . Conversely, substitution of the two major phosphorylation sites in Tax does not alter its transcriptional activity but destroys its oncogenicity in REF cells . As illustrated by the defect seen with provirus 395, Tax's transactivation activity is required for viral infectivity in vivo. In contrast, a provirus (Tax106+293) harboring mutated phosphorylation sites remains infectious and propagates at wild-type levels in sheep. In addition, the Tax106+293 mutant is pathogenic despite a loss in its ability to transform primary cells in vitro  (see Table 1). These findings suggest that a deficiency in Tax oncogenic potential as revealed by the REF immortalization does not correlate with leukemogenesis in vivo.
As previously mentioned, the BLV transcriptional promoter located in the 5' LTR contains suboptimal binding sequences for the CREB transcription factor. Remarkably, the cyclic-AMP responsive site (CRE) consensus "TGACGTCA" is never strictly conserved in any viral 21 bp element which invariably contains an imperfect substitution (for example, AGACGTCA, TGACGGCA, TGACCTCA). Restoring a perfect CRE sequence into the promoter increases LTR (long terminal repeat) promoter activity, as expected . However, the proviral loads are drastically reduced in sheep infected with a virus harboring this type of change (see Table 1). It is tempting to speculate that BLV may have evolved a self-attenuating process (perhaps for purposes of escaping immunosurveillence) which encourages the virus to maintain a less active promoter through suboptimal use of the CRE-dependent pathway. If this speculation is correct, then one thought is that transcriptional repression of viral expression may be a key factor which regulates viral persistence and spread. As mentioned in section 2, the activity of the viral LTR is also thought to be regulated by E-box motifs which overlap the CRE sites [88, 89]. However, an E-box mutant virus is infectious, replicates to wild-type levels and is pathogenic in sheep. These observations question the clear significance of the E-box motif in vivo  (and unpublished results).
Collectively the experimental findings from BLV research emphasize the dichotomy between subgenomic in vitro results and counterpart findings achieved using replicating viruses in vivo; they reinforce the critical need to perform pathogenesis studies in vivo.
5. Mecanisms of leukemogenesis
BLV is an exogenous virus which integrates randomly in the cellular genome
Viral infection is followed by a polyclonal expansion of a large and diverse population of lymphocytes harboring one to five integrated proviruses [122, 123, 244, 245, 246]. At later stages, a few cell clones predominate and the population evolves towards monoclonality in assays of viral integration. Proviral integration thus appears to be mandatory for the viral life cycle, although each integration event may not be perfect and on occasions some sequences are deleted [183, 184, 247]. In fact, these relatively frequent deletions typically affect the central structural genes and yield dead-end viruses that are unable to replicate in vivo [83, 184]. The emergence of these deletants might be a fortuitous consequence of viral replication following mistakes during reverse transcription, recombination or integration. However, the frequency at which these deletions occur in tumor samples suggests that they provide a selective advantage to the infected cell. In rare cases, it is even possible that a deleted provirus is the sole integrant within the host cell genome. However, it appears that at least one copy of the full-length BLV proviral genome is maintained in each animal throughout the course of the disease . Whether these replication-competent viruses complement the deletants, as observed for spleen focus-forming virus, is unknown. The defect within the proviruses is a consequence either of large deletions or of point mutations, but is not due to insertion of cellular sequences [248, 249]. Finally, BLV provirus integrates at random sites and, therefore, does not transform cells by insertional mutagenesis, as observed in ALV-induced tumors (Avian Leukosis Virus) [250, 251].
Low levels of viral expression are detected in vivo
An apparent paradox of BLV infection is that leukemogenesis proceeds in the absence of viral expression. In fact, lack of expression pertains to the large majority of detectable virus-infected cells [252, 253]. The first evidence is that BLV virions or viral proteins cannot be directly detected in the peripheral blood by any currently available technique (ELISA, flow cytometry, immunoprecipitation or western blotting). Second, viral transcripts from peripheral blood lymphocytes or tumors can only be amplified by means of very sensitive RT-PCR techniques [79, 180, 254, 255]. Third, using flow cytometry cell sorting and subsequent RT-PCR, only about one B lymphocyte out of 10,000 is found to express tax/rex mRNA during persistent lymphocytosis. Fourth, only rare cells in the peripheral blood (1 in 50,000) contain enough BLV transcripts to be readily identified by in situ hybridization [256, 257]. A potential repression mechanism of viral expression involves a plasma factor related to fibronectin [258, 259, 260] and inhibited by a platelet lysate . However, expression of BLV in samples of whole blood from BLV-infected cattle is activated immediately upon incubation at 37°C in the absence of any exogenous factors except for anticoagulants or the removal of blood cells from plasma .
As early as in 1969, Miller  showed that cultivation of infected peripheral blood mononuclear cells leads to expression of viral antigens. This process has been extensively characterized to identify the involved pathways: it appears that concanavalin A [263, 264], phytohemagglutinin (PHA) [256, 265], lipopolysaccharide (LPS) [179, 266], phorbol esters (PMA) and calcium ionophores [24, 267, 268] activate viral protein synthesis. The presence of T cells increases [264, 269, 270], but is not strictly required for viral expression by the infected B lymphocytes. As revealed by a series of relatively specific inhibitors, the metabolic pathways involved in viral expression include protein kinase C, calmodulin and intracellular calcium mobilisation. More physiological stimuli of viral expression include cross-linking of membrane IgM or interactions with CD40 ligand, mimicking BCR and T cell activation, respectively [243, 256, 268]. Finally, viral transcription is activated by components of fetal bovine serum.
Altogether, these data indicate that viral expression can be augmented by molecules that mimic B cell activation by immune cells. As presented in this paragraph, the traditional and dogmatic model postulates that cells are latently infected and express viral proteins only upon transient ex vivo cell culture. This concept faces a series of objections and we propose another model in section 6.
Altered gene expression of cytokines
Interleukins: IL2, IL6, IL10 and IL12
A first described cytokine network interconnects interleukin-10 (IL-10), viral expression and B-cell proliferation in BLV-infected cattle. IL-10 mRNA is over expressed in cows with persistent lymphocytosis [271, 272]. In cell culture of PBMCs, IL-10 inhibits expression of COX-2 as well as antigen-specific cell proliferation. IL-10 suppresses synthesis of a macrophage-derived COX-2 product, prostaglandin E2, that stimulates virus expression [273, 274].
Although reported data on IL2 expression during the course of BLV-infection are discordant, it is agreed that elevated levels of this cytokine are synthesized in mitogen-stimulated PBMCs from asymptomatic and PL cattle [225, 264, 275, 276, 277, 278]. Furthermore, in isolated B lymphocytes from PL cows, IL-2 increases viral CA protein synthesis, IL-2 receptor expression, and triggers proliferation.
T cells isolated from lymph nodes and peripheral blood of BLV-infected cattle express IL-2 mRNAs . However, the amounts of IL-2 mRNAs are significantly reduced in CD4+ T cells from PL cows as compared to controls; on the other hand, no significant differences in the frequencies of CD4+ T cells expressing these cytokine mRNAs are observed.
Although IL-6 mRNAs are barely detectable in fresh B cells from PL cows, transcripts encoding this cytokine are strongly and rapidly upregulated after cell culture . Furthermore, levels of IL-6 are significantly higher in the sera of BLV infected cows with PL as well as in PBMC cultures following in vitro exposure to BLV antigens . When exogenous IL-6 is added to infected cells in vitro, viral expression is strongly suppressed, suggesting that IL-6 plays a contributory role to viral latency.
Finally, elevated levels of IL-12 in asymptomatic and PL cattle are expressed by mitogen-stimulated PBMC . However, IL-12 p40 mRNA expression is significantly decreased in PL cattle compared to aleukemic animals .
The role of tumour necrosis factor alpha (TNFα) in BLV replication has clearly been demonstrated in TNF-/- knockout mice . In sheep inoculated with BLV, expression of TNFα receptor type 1 mRNA (TNF-R1) is down-regulated while TNF-R2 mRNA remains constant. BLV-infected PBMCs express membrane-bound TNFα and proliferate in response to TNFα [285, 286]. Furthermore, TNFα expression is higher in sheep that resist BLV infection after vaccination .
In BLV-infected cattle, the mean mRNA expression level for TNF-α is higher in the spontaneously proliferating and antigen-induced PBMC population [271, 272, 281, 288]. When exogenous TNF-α is added to BLV infected cells in vitro, viral expression is strongly suppressed. Cells isolated from PL cattle exhibit increased proliferative responses in the presence of recombinant bovine TNF-α  and express significantly higher TNF-R2 mRNA levels although no difference is found in TNF-R1 mRNA levels. Most cells expressing TNF-R2 are CD5+ or sIgM+ cells and are less prone to TNFα-induced apoptosis .
As expected by its antiviral activity, recombinant bovine IFN-γ suppresses replication of ovine BLV-infected cells in vitro . In addition, sheep, which show augmented mRNA expression of IFNγ, have lower proviral loads . When BLV-infected cattle are inoculated intraperitoneally with recombinant bovine IFN-γ, γδ T cells increase soon after a period of transient fever whereas the number of BLV-infected B lymphocytes remains low during one week . This experiment thus directly illustrates the potency of IFNγ to inhibit viral spread.
IFNγ mRNA is detected in the T-cell population isolated from lymph nodes of BLV-infected cattle [279, 282]. In PBMCs, IFN-γ mRNA expression increases 4 weeks after infection  but the antiviral activity remains intriguingly unaffected . In aleukemic cattle, IFNγ mRNA expression is significantly increased compared to those in cattle with persistent lymphocytosis . Furthermore, IFN-γ is elevated in pokeweed mitogen-stimulated cells from asymptomatic cattle but not from PL animals .
Recently, another form of interferon, IFN-τ, was reported as a potential anti-viral protein in cattle .
Host cell genetics
BLV-induced leukemogenesis is preceded by a long lasting chronic disease characterized by accumulation of genetic modifications such as mutation of p53 within the host genome [296, 297, 298, 299]. Approximately half of the solid tumors induced by BLV in cattle contain a mutated p53 gene while very few mutations are found in preneoplastic B cells. These mutations interfere with essential p53 functions required for transactivation and suppression of cell growth . In addition, the ratio of Bcl2 to Bax which is believed to predetermine the susceptibility to a given apoptotic stimulus is increased at advanced stages of disease in cattle . In contrast, the p53 gene is not mutated at any stage of disease in sheep .
Tumors cells accumulate clonal abnormalities and are hyperdiploid . The most common aberrations are the acquisition of additional small chromosomes, trisomy, Robertsonian translocations and isochromosome rearrangements. Whether these abnormalities are required to achieve full malignancy or are just bystanders of transformation is currently unknown. However, it is likely that these chromosomal alterations acquired during a long multistep process provide a selective growth advantage to the tumor cells.
The genetic profile of the host genome also predisposes to tumor development . A major factor involved in clinical progression of BLV-infected animals is mediated by the bovine major histocompatibility complex (BoLA) [304, 305]. Genetic resistance and susceptibility to persistent lymphocytosis (PL), have been mapped to structural motifs in bovine MHC DRB3 (class II) alleles . Haplotype DQA*12-DQB*12-DRB2*3A-DRB3.2*8 is associated with a risk factor for subclinical progression to PL in BLV-infected animals, whereas DQA*3A-DQB*3A-DRB2*2A-DRB3.2*11 correlates with resistance . Animals with the PL-resistance associated DRB3.2*11 allele have significantly fewer BLV-infected B cells than do age- and seroconversion-matched cows with DRB3 alleles associated with susceptibility to PL . Furthermore, another polymorphism in the promoter region of TNF-α gene (-824G allele) may contribute to the progression of lymphoma in BLV-infection 
In sheep, genetic predisposition to development of leukemia correlates with a particular MHC-II DRB1 allele. The Arg-Lys (RK) and the Ser-Arg (SR) at positions 70/71 of the OLA-DRβ1 domain are associated with resistance and susceptibility, respectively, to development of lymphoma . Higher levels of IFN-γ are found in animals with RK/RK genotype  most probably modulating disease progression.
The susceptibility to the polyclonal expansion of BLV-infected B lymphocytes is thus associated with specific alleles of the major histocompatibility complex system.
Host humoral and cytotoxic immune responses
Natural or iatrogenic transmission of BLV primarily involves the transfer of infected cells via blood or milk [8, 308]. The processes occurring after this primary infection still remain obscure. One of the earliest indications of infection is the onset of a humoral anti-viral response at about 1–8 weeks post-inoculation [308, 312, 313]. Antibodies recognizing epitopes from structural (envelope gp51 and capsid p24) and regulatory proteins (Tax and Rex) are synthesized at high titers. Some of these antibodies are directly lytic for BLV-producing cells . The level of antibody-mediated cytolytic activity increases with progression of the disease towards the acute phase .
Almost concomitant with the early seroconversion period, cytotoxic T-lymphocytes (CTL) specific for Tax and Envelope epitopes appear in the peripheral blood [147, 285]. Compared to humans, a peculiarity of cattle is that γδ T-lymphocytes are major players in this cytotoxic response . BLV infection also triggers both a virus-dependent and a virus-independent CD4 helper T cell response [144, 317, 318].
It thus appears that a very active humoral and cytotoxic immune response is initiated soon after BLV infection (reviewed in [285, 319]). Importantly, these anti-viral activities amplify and persist throughout the animal's life indicating that the immune system is permanently stimulated by BLV antigens. The persistence of this immune response is relatively unexpected for a chronic infection, at least if associated with a latent virus. However, cytotoxic and helper associated functions weaken in BLV-infected animals, as the disease progresses, as supported by a lower spontaneous recovery from Trichophyton verrucosum [285, 320]
6. Cell dynamics of viral infection
Is BLV silent?
Although BLV expression is detected in a minority of viable cells, a strong cytotoxic and humoral immune response is induced within the infected host. Experimental evidence (i.e. in situ hybridization, flow cytometry, RT-PCR) favors a model postulating that the virus is latent in the very large majority of detectable cells (i.e. those that escape from immune response and can be isolated and observed ex vivo). The latency of BLV in vivo and its reactivation upon ex vivo culture thus became a standing dogma. There are however a series of caveats in this model. Indeed, the maintenance of a vigorous anti-viral immune response in infected animals indicates that some degree of virus expression must occur in vivo. Furthermore, BLV transcription can even be detected in samples of whole blood upon incubation at 37°C without addition of any exogenous factor except anticoagulants . Then, why would this process not be ongoing continuously in infected cells in vivo? If anticoagulants do not activate viral expression, it is unlikely, although not impossible, that the simple removal of blood would be sufficient to induce BLV transcription. Alternatively, we favor the idea that viral expression occurs permanently in a subpopulation of infected cells, which are very efficiently killed by the immune system. The cytotoxic and humoral responses are however unable to destroy cells in which viral transcription is completely silenced.
How does the virus replicate?
Viral replication occurs via the replicative cycle after expression of virions able to infect novel target cells. Alternatively, the integrated proviruses can expand by mitosis of the host cell by a process referred to as clonal expansion . Semiquantitative inverse PCR amplification of the cellular sequences flanking the BLV provirus has revealed that the viral load results almost exclusively from clonal expansion of infected cells . Importantly, the premalignant cellular clones from which the tumor originates can be detected as early as a few weeks after experimental infection. In fact, the latency period preceding onset of leukemia/lymphoma is characterized by a fluctuation in the abundance of different cellular clones harboring an integrated provirus. Malignancy of a given clone correlates with the accumulation of somatic mutations revealing a decrease in the genetic stability of the expanding infected cell. During the asymptomatic phase, most of the proviral load is sustained by mitosis of the infected cell. Efficient virus replication and infection of new target cells via virions and/or virological synapses seem to occur mostly, if not almost exclusively, during a very short period following viral inoculation (so-called primary infection). However, it is still possible that the replicative cycle is ongoing continuously but the net outcome of this process does not contribute significantly to the observed viral load, because of an efficient immune response.
Two key and related questions remain to be solved: why is the abundance of the infected cell clones fluctuating? And what is the driving force of the clonal expansion process? Based on the extensively described oncogenic properties of Tax, our tenet is that this virally encoded protein triggers cell proliferation.
Is BLV inhibiting apoptosis?
When peripheral blood mononuclear cells from BLV-infected sheep are transiently maintained in culture for a few hours, the levels of B cell apoptosis are reduced compared to normal controls [322, 323]. The most straightforward interpretation is that BLV interferes with spontaneous apoptosis of B lymphocytes. This process requires at least in part a caspase 8-dependent pathway regardless of viral infection . Pharmaceutical depletion of reduced glutathione (namely, gamma-glutamyl-L-cysteinyl-glycine [GSH]) by using ethacrynic acid or 1-pyrrolidinecarbodithioic acid specifically counters the inhibition of spontaneous apoptosis conferred indirectly by protective BLV-conditioned media; conversely, exogenously provided membrane-permeable GSH-monoethyl ester restores cell viability in B lymphocytes of BLV-infected sheep. Most importantly, intracellular GSH levels correlate with virus-associated protection against apoptosis but not with general inhibition of cell death induced by polyclonal activators, such as phorbol esters and ionomycin. Similar evaluations of spontaneous apoptosis in cattle yielded a very broad range of spontaneous apoptosis mainly depending on the experimental conditions [97, 325, 326].
Cell kinetics in vivo
Several markers of proliferation (PCNA, KI67 and myc) are overexpressed in B lymphocytes from tumors and PBMCs isolated from animals with PL, suggesting an increased replicative capacity of these cells [327, 328, 329]. However, lymphocyte homeostasis is the result of a critical balance between cell proliferation and death. Disruption of this equilibrium can lead to the onset of leukemia. Thus an increase in lymphocyte number can be potentially explained by either one or both of the above parameters.
To further gain insight into the processes mediating pathogenesis, it is necessary to determine the kinetic parameters which sustain the dynamics of the different cell populations in infected animals. The proliferation rates in BLV-infected and healthy sheep were initially determined using intravenous injection of bromodeoxyuridine (BrdU). This in vivo approach revealed that B-lymphocytes are proliferating significantly faster in BLV-positive asymptomatic and lymphocytic sheep than in uninfected controls (average proliferation rate of 0.020 day-1 versus 0.011 day-1), meaning that an excess of 0.9 % cells (the difference between 2 and 1.1%) are produced by proliferation each day . The difference in the proliferation rates becomes even more evident at the terminal neoplastic stage of the disease (proliferation rate increases by up to tenfold). Cells in S/G2/M then also appear in the peripheral blood (our unpublished results) similar to findings documented for acute cases of human non-viral leukemia . In contrast, the death rates of the BrdU-positive cells are not significantly different between aleukemic BLV-infected and control sheep.
In the natural host, BLV-infected cattle, the cell proliferation rates in asymptomatic and control animals are not significantly different . Surprisingly, the PL stage is characterized by a decreased B cell turnover resulting from a reduction of cell death as well as from an overall impairment of proliferation. Paradoxically, an excess of B lymphocytes in the peripheral blood in PL animals correlates with a reduction of cell proliferation, suggesting that a mechanism of feedback regulation controls lymphocyte homeostasis. Of note, the lymphocyte turnover is also reduced in other lymphoaccumulative diseases such as, CLL (chronic lymphocytic leukemia), a B CD5+ chronic leukemia in human (J. Defoiche, submitted). The reduced dynamic parameters measured in cattle thus contrast with the accelerated kinetics observed in experimentally infected sheep. Whether these observations relate to the differences in disease acuteness in the two host species remains a tempting but still open assumption.
Cells expressing viral proteins cannot be directly observed in the peripheral blood of the infected animals at any stage of the disease. However, viral expression can be induced upon transient short term culture. Surprisingly, very few (if any) cells spontaneously synthesizing CA antigen undergo proliferation in vivo [325, 330]. Amongst all infected cells proliferating in vivo as measured by BrdU uptake, none is found to express viral protein. Since lymphocytes synthesizing p24gag are spared from apoptosis ex vivo, p24+BrdU+ double positive cells are not lost during culturing but appear to have been eliminated in vivo. If we postulate that viral expression and cell activation are closely linked, as widely illustrated in the literature, the lack of p24+BrdU+ double positive cells then reveals a very efficient negative selection which occurs in vivo. Another non-exclusive interpretation would be that only a subpopulation of infected cells is allowed to proliferate (i.e. incorporate BrdU) provided that no viral proteins are expressed. However, this model does not fit with the progressive accumulation of provirus-positive cells, if proliferation is triggered by a viral protein. What would indeed be the selective advantage of a cell carrying a completely silent provirus?
Whatever the involved mechanisms, these kinetic studies cast light onto a very active process of immune selection directed towards proliferating infected cells that express an integrated provirus.
Lymphocyte trafficking in lymphoid organs
Collectively, quantification of the dynamic parameters deduced from BrdU and CFSE kinetics shows that the excess of proliferation in lymphoid organs can be compensated by increased death of the peripheral blood cell population. An important issue that remains to be clarified is to identify the anatomic site required for this cell destruction. In this context, our recent experiments revealed that the spleen is a major lymphoid tissue regulating infected cell dynamics . Indeed, the cell death rates pertaining to the peripheral blood cells of BLV-infected and control sheep are similar after splenectomy, revealing a key role of the spleen in B-lymphocyte dynamics.
Since very few lymphocytes expressing viral proteins can be detected directly in vivo, the frequency of infected cells which survive the host immune pressure is low. Also, this process would only marginally affect the very large majority of infected cells containing a silent virus (or a modestly expressed virus). The net outcome of this model would be a global stability of the proviral loads with some fluctuations of individual clones, as revealed by long term follow-up of proviral integration sites by ligation-mediated PCR. Although the mechanism is still unknown, variations in the abundance of provirus-positive cell clones could be due to differential antigen stimulation or to modulation of the proportions of individual progeny cells to express virus. Hence, cells isolated from sheep at terminal stages of the disease lose their ability to efficiently express virus ex vivo even in the presence of potent polyclonal activators such as phorbol esters (our unpublished results). Ultimately, a fully transformed cell clone containing a deleted replication defective provirus can even outgrow and induce leukemia .
A hypothetical model, which may also apply to HTLV , is needed to reconcile the following experimental findings which include the oncogenic potential of Tax, the continuous stimulation of the immune system, the low levels of detectable cells expressing viral proteins in vivo, the apparent stability of individual proviral clones, and the dynamic parameters of cell proliferation and cell death. During BLV chronic infection, the host-pathogen interplay is characterized by a very dynamic kinetics generating equilibrium between a virus attempting to proliferate under a tight control exerted by the immune response. In this model, the virus permanently transits between a latent and transcriptionally active phase resulting in the progressive accumulation of viable infected cells. Occurrence of somatic mutations associated with genetic instability in these cells ultimately permits the outgrowth of a transformed clone, leading to leukemia.
7. Modulation of viral expression as therapy
In the absence of ex vivo cell culture, the infected lymphocytes apparently do not express any viral protein in the peripheral blood and rest in the G0/G1 phase of the cell cycle. These apparently quiescent cells may undergo spontaneous cell proliferation and express virions upon transient short-term culturing. Agents known to activate immune cells polyclonally cause an increase in the number of cells containing BLV RNA . Viral expression may thus be induced by activation of the host cell after immune-mediated stimulation.
Among a growing list of HDAC inhibitors, valproate (the sodium salt of 2-propylpentanoic acid) offers a series of advantages . Widely used for several decades in treating epilepsy, this short-chain fatty acid has a very high bioavailability, exhibits very low toxicity in adults and, with a half life of 16–17 hours, has suitable pharmacokinetic properties in vivo. Therefore, valproate has been selected to evaluate the effectiveness of gene activation chemotherapy in leukemic sheep. Indeed, valproate effectively activates BLV gene expression in transient transfection experiments and in short-term cultures of primary B-lymphocytes . In vivo, valproate administration, in the absence of any other cytotoxic drug, is efficient for the treatment of leukemia/lymphoma in sheep, demonstrating the proof-of-concept of a therapy that targets the expression of viral and/or cellular genes. Interestingly, over a long term period, valproate treatment alters neither the cell numbers in control sheep nor other lymphocyte populations in BLV-infected animals, revealing a relative innocuousness of the therapy.
The mechanism by which valproate specifically decreases the number of leukemic cells remains to be determined. Amongst numerous hypotheses, we propose a model based on transient activation of cellular and/or viral expression leading to apoptosis by intrinsic (for instance dependent on mitochondrial regulated checkpoints) or extrinsic mechanisms related to membrane-bound receptors (Fas, TRAIL,) [348, 349, 350]. It is possible that the involved mechanisms are completely independent of viral infection as indicated by our ongoing experiments in mesothelioma and chronic lymphocytic leukemia cells (F. Vandermeers and A. Bouzar). Alternatively, a very attractive model would include the induction of viral expression and destruction by the immune response.
Based on the numerous similarities between BLV and HTLV, we propose to investigate the therapeutic potential of a valproate treatment in TSP/HAM and ATL. Indeed, there are presently no satisfactory therapies for these diseases so far. Palliative treatments for HAM/TSP include steroids to decrease inflammation [351, 352, 353]. Attempts to treat HAM/TSP by interfering with cell invasion into the CNS using inhibitors of matrix metalloproteinases  have been unsuccessful. Similarly, other strategies aimed at inhibiting cell activation and/or viral replication with cytokines (IFN-α or -β)  or anti-viral compounds [355, 356, 357, 358] did not show sufficient efficacy. ATL patients have a very poor prognosis because of intrinsic chemoresistance and severe immunosuppression. Non-targeted combinations of chemotherapy (CHOP) yield primary responses but lack a significant effect on complete remission and survival . Besides promising new drugs such as arsenic trioxide and proteasome inhibitors, additional therapies are needed. In this context, valproate-based gene activation therapy should be considered.
BLV is the etiologic agent of enzootic bovine leukemia in cattle, a disease which (depending on the part of the world) is either eradicated or simply ignored. However, the experimental infection of sheep with BLV provides an interesting model of leukemogenesis. In particular, we review here the viral genetic determinants required for pathogenesis and present recent understanding of the homeostatic regulation of leukemic B lymphocytes in BLV-infected sheep. We also propose a novel therapeutic concept targeting the expression of viral genes and involving the immune response. This strategy might also hold promise for treating adult T cell leukemia (ATL) or human T-lymphotropic virus-associated myelopathy/tropical spastic paraparesis (HAM/TSP), diseases for which no satisfactory treatment currently exists.
We would like to warmly thank KT Jeang for helpful suggestions and for very careful editing of this manuscript. This work was supported by the 6th framework program INCA project of the European Commission (project INCA LSHC-CT-2005-018704), the "Fonds national de la recherche scientifique" (FNRS) and the Télévie, the Belgian Foundation against Cancer, the Bekales Foundation, and the CGRI (Commissariat général des relations internationales). NG ("Télévie" Fellows), AF (Research Fellow), MB (FRIA Fellow), CB, HB and JD ("Télévie" Fellows) and RK and LW (Research Directors) are members of the FNRS. We also wish to thank our numerous collaborators who contributed to our previous research projects on BLV, and in particular during the last 5 year period: Becca Asquith, Charles Bangham, Delphine Collete, Christophe Debacq, François Debande, Jack Hay, Geneviève Jean, Pierre Kerkhofs, Laurent Lefèbvre, Jean-Marie Londes, Charafa Merezak, Franck Mortreux, Daniel Portetelle, Maria Teresa Sanchez-Alcaraz, Isabelle Schwartz-Cornil, Jean-Claude Twizere, Patrice Urbain, Carine Van Lint and Eric Wattel.
- 1.Leisering A: . Ber Vet -Wes Kgr Sachen. 1871, 16: 15-Google Scholar
- 3.Olson C, Miller J: . Enzootic bovine leukosis and bovine leukemia virus Martinus Nijhoff Publishing, Boston. 1987, 3-Google Scholar
- 4.Willems L, Burny A, Dangoisse O, Collete D, Dequiedt F, Gatot JS, Kerkhofs P, Lefebvre L, Merezak C, Portetelle D, Twizere JC, Kettmann R: Bovine leukemia virus as a model for human T-cell leukemia virus. Current Topics in Virology. 1999, 139-167.Google Scholar
- 24.Camargos MF, Pereda A, Stancek D, Rocha MA, Reis JK, Greiser-Wilke I, Leite RC: Molecular characterization of the env gene from Brazilian field isolates of Bovine Leukemia Virus. Virus Genes. 2006Google Scholar
- 29.Okada K, Nakae N, Kuramochi K, Yin SA, Ikeda M, Takami S, Hirata T, Goryo M, Numakunai S, Takeshima SN, Takahashi M, Tajima S, Konnai S, Onuma M, Aida Y: Bovine leukemia virus high tax molecular clone experimentally induces leukemia/lymphoma in sheep. J Vet Med Sci. 2005, 67: 1231-1235. 10.1292/jvms.67.1231.PubMedGoogle Scholar
- 40.Altanerova V, Portetelle D, Kettmann R, Altaner C: Infection of rats with bovine leukaemia virus: establishment of a virus-producing rat cell line. J Gen Virol. 1989, 70 ( Pt 7): 1929-1932.Google Scholar
- 58.Mahieux R, Gessain A: [New human retroviruses: HTLV-3 and HTLV-4]. Med Trop (Mars ). 2005, 65: 525-528.Google Scholar
- 59.Wolfe ND, Heneine W, Carr JK, Garcia AD, Shanmugam V, Tamoufe U, Torimiro JN, Prosser AT, Lebreton M, Mpoudi-Ngole E, McCutchan FE, Birx DL, Folks TM, Burke DS, Switzer WM: Emergence of unique primate T-lymphotropic viruses among central African bushmeat hunters. Proc Natl Acad Sci U S A. 2005, 102: 7994-7999. 10.1073/pnas.0501734102.PubMedCentralPubMedGoogle Scholar
- 62.Sagata N, Yasunaga T, Ogawa Y, Tsuzuku-Kawamura J, Ikawa Y: Bovine leukemia virus: unique structural features of its long terminal repeats and its evolutionary relationship to human T-cell leukemia virus. Proc Natl Acad Sci U S A. 1984, 81: 4741-4745. 10.1073/pnas.81.15.4741.PubMedCentralPubMedGoogle Scholar
- 63.Dube S, Bachman S, Spicer T, Love J, Choi D, Esteban E, Ferrer JF, Poiesz BJ: Degenerate and specific PCR assays for the detection of bovine leukaemia virus and primate T cell leukaemia/lymphoma virus pol DNA and RNA: phylogenetic comparisons of amplified sequences from cattle and primates from around the world. J Gen Virol. 1997, 78 ( Pt 6): 1389-1398.PubMedGoogle Scholar
- 87.Merezak C, Pierreux C, Adam E, Lemaigre F, Rousseau GG, Calomme C, Van Lint C, Christophe D, Kerkhofs P, Burny A, Kettmann R, Willems L: Suboptimal enhancer sequences are required for efficient bovine leukemia virus propagation in vivo: implications for viral latency. J Virol. 2001, 75: 6977-6988. 10.1128/JVI.75.15.6977-6988.2001.PubMedCentralPubMedGoogle Scholar
- 88.Calomme C, Dekoninck A, Nizet S, Adam E, Nguyen TL, Van den BA, Willems L, Kettmann R, Burny A, Van Lint C: Overlapping CRE and E box motifs in the enhancer sequences of the bovine leukemia virus 5' long terminal repeat are critical for basal and acetylation-dependent transcriptional activity of the viral promoter: implications for viral latency. J Virol. 2004, 78: 13848-13864. 10.1128/JVI.78.24.13848-13864.2004.PubMedCentralPubMedGoogle Scholar
- 94.Calomme C, Nguyen TL, de Launoit Y, Kiermer V, Droogmans L, Burny A, Van Lint C: Upstream stimulatory factors binding to an E box motif in the R region of the bovine leukemia virus long terminal repeat stimulates viral gene expression. J Biol Chem. 2002, 277: 8775-8789. 10.1074/jbc.M107441200.PubMedGoogle Scholar
- 95.Kiermer V, Van Lint C, Briclet D, Vanhulle C, Kettmann R, Verdin E, Burny A, Droogmans L: An interferon regulatory factor binding site in the U5 region of the bovine leukemia virus long terminal repeat stimulates Tax-independent gene expression. J Virol. 1998, 72: 5526-5534.PubMedCentralPubMedGoogle Scholar
- 97.Nguyen TL, Calomme C, Wijmeersch G, Nizet S, Veithen E, Portetelle D, de Launoit Y, Burny A, Van Lint C: Deacetylase inhibitors and the viral transactivator TaxBLV synergistically activate bovine leukemia virus gene expression via a cAMP-responsive element- and cAMP-responsive element-binding protein-dependent mechanism. J Biol Chem. 2004, 279: 35025-35036. 10.1074/jbc.M404081200.PubMedGoogle Scholar
- 103.Mamoun RZ, Astier T, Guillemain B, Duplan JF: Bovine lymphosarcoma: expression of BLV-related proteins in cultured cells. J Gen Virol. 1983, 64 (Pt 9): 1895-1905.Google Scholar
- 104.Oroszlan S, Copeland TD, Henderson LE, Stephenson JR, Gilden RV: Amino-terminal sequence of bovine leukemia virus major internal protein: homology with mammalian type C virus p30 structural proteins. Proc Natl Acad Sci U S A. 1979, 76: 2996-3000. 10.1073/pnas.76.6.2996.PubMedCentralPubMedGoogle Scholar
- 110.Mager A, Masengo R, Mammerickx M, Letesson JJ: T cell proliferative response to bovine leukaemia virus (BLV): identification of T cell epitopes on the major core protein (p24) in BLV-infected cattle with normal haematological values. J Gen Virol. 1994, 75 ( Pt 9): 2223-2231.Google Scholar
- 111.Willems L, Kerkhofs P, Attenelle L, Burny A, Portetelle D, Kettmann R: The major homology region of bovine leukaemia virus p24gag is required for virus infectivity in vivo. J Gen Virol. 1997, 78 ( Pt 3): 637-640.Google Scholar
- 113.Zandomeni RO, Carrera-Zandomeni M, Esteban E, Ferrer JF: The trans-activating C-type retroviruses share a distinct epitope(s) that induces antibodies in certain infected hosts. J Gen Virol. 1991, 72 ( Pt 9): 2113-2119.Google Scholar
- 132.Coulston J, Naif H, Brandon R, Kumar S, Khan S, Daniel RC, Lavin MF: Molecular cloning and sequencing of an Australian isolate of proviral bovine leukaemia virus DNA: comparison with other isolates. J Gen Virol. 1990, 71 ( Pt 8): 1737-1746.Google Scholar
- 133.Rice NR, Stephens RM, Gilden RV: Sequence analysis of the bovine leukemia virus genome. Enzootic bovine leukosis and bovine leukemia virus Martinus Nijhoff Publishing, The Hague, The Netherlands. 1987, 115-144.Google Scholar
- 136.Bruck C, Rensonnet N, Portetelle D, Cleuter Y, Mammerickx M, Burny A, Mamoun R, Guillemain B, Van der Maaten MJ, Ghysdael J: Biologically active epitopes of bovine leukemia virus glycoprotein gp51: their dependence on protein glycosylation and genetic variability. Virology. 1984, 136: 20-31. 10.1016/0042-6822(84)90244-7.PubMedGoogle Scholar
- 142.Callebaut I, Mornon JP, Burny A, Portetelle D: The bovine leukemia virus (BLV) envelope glycoprotein gp51 as a general model for the design of a subunit vaccine against retroviral infection: mapping of functional sites through immunological and structural data. Leukemia. 1994, 8 Suppl 1: S218-S221.PubMedGoogle Scholar
- 153.Gatot JS, Callebaut I, Mornon JP, Portetelle D, Burny A, Kerkhofs P, Kettmann R, Willems L: Conservative mutations in the immunosuppressive region of the bovine leukemia virus transmembrane protein affect fusion but not infectivity in vivo. J Biol Chem. 1998, 273: 12870-12880. 10.1074/jbc.273.21.12870.PubMedGoogle Scholar
- 155.Voneche V, Portetelle D, Kettmann R, Willems L, Limbach K, Paoletti E, Ruysschaert JM, Burny A, Brasseur R: Fusogenic segments of bovine leukemia virus and simian immunodeficiency virus are interchangeable and mediate fusion by means of oblique insertion in the lipid bilayer of their target cells. Proc Natl Acad Sci U S A. 1992, 89: 3810-3814. 10.1073/pnas.89.9.3810.PubMedCentralPubMedGoogle Scholar
- 157.Gatot JS, Callebaut I, Van Lint C, Demonte D, Kerkhofs P, Portetelle D, Burny A, Willems L, Kettmann R: Bovine leukemia virus SU protein interacts with zinc, and mutations within two interacting regions differently affect viral fusion and infectivity in vivo. J Virol. 2002, 76: 7956-7967. 10.1128/JVI.76.16.7956-7967.2002.PubMedCentralPubMedGoogle Scholar
- 159.Beaufils P, Choquet D, Mamoun RZ, Malissen B: The (YXXL/I)2 signalling motif found in the cytoplasmic segments of the bovine leukaemia virus envelope protein and Epstein-Barr virus latent membrane protein 2A can elicit early and late lymphocyte activation events. EMBO J. 1993, 12: 5105-5112.PubMedCentralPubMedGoogle Scholar
- 162.Grange MP, Blot V, Delamarre L, Bouchaert I, Rocca A, Dautry-Varsat A, Dokhelar MC: Identification of two intracellular mechanisms leading to reduced expression of oncoretrovirus envelope glycoproteins at the cell surface. J Virol. 2000, 74: 11734-11743. 10.1128/JVI.74.24.11734-11743.2000.PubMedCentralPubMedGoogle Scholar
- 170.Lefebvre L, Vanderplasschen A, Ciminale V, Heremans H, Dangoisse O, Jauniaux JC, Toussaint JF, Zelnik V, Burny A, Kettmann R, Willems L: Oncoviral bovine leukemia virus G4 and human T-cell leukemia virus type 1 p13(II) accessory proteins interact with farnesyl pyrophosphate synthetase. Journal of Virology. 2002, 76: 1400-1414. 10.1128/JVI.76.15.7843-7854.2002.PubMedCentralPubMedGoogle Scholar
- 183.Van den BA, Cleuter Y, Chen G, Portetelle D, Mammerickx M, Zagury D, Fouchard M, Coulombel L, Kettmann R, Burny A: Even transcriptionally competent proviruses are silent in bovine leukemia virus-induced sheep tumor cells. Proc Natl Acad Sci U S A. 1988, 85: 9263-9267. 10.1073/pnas.85.23.9263.Google Scholar
- 185.Van den BA, Bagnis C, Ciesiolka M, Cleuter Y, Gelderblom H, Kerkhofs P, Griebel P, Mannoni P, Burny A: In vivo rescue of a silent tax-deficient bovine leukemia virus from a tumor-derived ovine B-cell line by recombination with a retrovirally transduced wild-type tax gene. J Virol. 1999, 73: 1054-1065.Google Scholar
- 186.Twizere JC, Kruys V, Lefebvre L, Vanderplasschen A, Collete D, Debacq C, Lai WS, Jauniaux JC, Bernstein LR, Semmes OJ, Burny A, Blackshear PJ, Kettmann R, Willems L: Interaction of retroviral Tax oncoproteins with tristetraprolin and regulation of tumor necrosis factor-alpha expression. J Natl Cancer Inst. 2003, 95: 1846-1859.PubMedGoogle Scholar
- 191.Sakurai M, Taneda A, Nagoya H, Sekikawa K: Construction and functional characterization of mutants of the bovine leukaemia virus trans-activator protein p34tax. J Gen Virol. 1991, 72 ( Pt 10): 2527-2531.Google Scholar
- 193.Willems L, Grimonpont C, Heremans H, Rebeyrotte N, Chen G, Portetelle D, Burny A, Kettmann R: Mutations in the bovine leukemia virus Tax protein can abrogate the long terminal repeat-directed transactivating activity without concomitant loss of transforming potential. Proc Natl Acad Sci U S A. 1992, 89: 3957-3961. 10.1073/pnas.89.9.3957.PubMedCentralPubMedGoogle Scholar
- 194.Tajima S, Aida Y: The region between amino acids 245 and 265 of the bovine leukemia virus (BLV) tax protein restricts transactivation not only via the BLV enhancer but also via other retrovirus enhancers. J Virol. 2000, 74: 10939-10949. 10.1128/JVI.74.23.10939-10949.2000.PubMedCentralPubMedGoogle Scholar
- 196.Tajima S, Takahashi M, Takeshima SN, Konnai S, Yin SA, Watarai S, Tanaka Y, Onuma M, Okada K, Aida Y: A mutant form of the tax protein of bovine leukemia virus (BLV), with enhanced transactivation activity, increases expression and propagation of BLV in vitro but not in vivo. J Virol. 2003, 77: 1894-1903. 10.1128/JVI.77.3.1894-1903.2003.PubMedCentralPubMedGoogle Scholar
- 199.Willems L, Grimonpont C, Kerkhofs P, Capiau C, Gheysen D, Conrath K, Roussef R, Mamoun R, Portetelle D, Burny A, Adam E, Lefebvre L, Twizere JC, Heremans H, Kettmann R: Phosphorylation of bovine leukemia virus Tax protein is required for in vitro transformation but not for transactivation. Oncogene. 1998, 16: 2165-2176. 10.1038/sj.onc.1201765.PubMedGoogle Scholar
- 201.Szynal M, Cleuter Y, Beskorwayne T, Bagnis C, Van Lint C, Kerkhofs P, Burny A, Martiat P, Griebel P, Van den BA: Disruption of B-cell homeostatic control mediated by the BLV-Tax oncoprotein: association with the upregulation of Bcl-2 and signaling through NF-kappaB. Oncogene. 2003, 22: 4531-4542. 10.1038/sj.onc.1206546.PubMedGoogle Scholar
- 202.Klener P, Szynal M, Cleuter Y, Merimi M, Duvillier H, Lallemand F, Bagnis C, Griebel P, Sotiriou C, Burny A, Martiat P, Van den BA: Insights into gene expression changes impacting B-cell transformation: cross-species microarray analysis of bovine leukemia virus tax-responsive genes in ovine B cells. J Virol. 2006, 80: 1922-1938. 10.1128/JVI.80.4.1922-1938.2006.PubMedCentralPubMedGoogle Scholar
- 205.Twizere JC, Springael JY, Boxus M, Burny A, Dequiedt F, Dewulf JF, Duchateau J, Portetelle D, Urbain P, Van Lint C, Green PL, Mahieux R, Parmentier M, Willems L, Kettmann R: Human T-cell leukemia virus type-1 Tax oncoprotein regulates G protein signaling. Blood. 2006Google Scholar
- 211.Stott ML, Thurmond MC, Dunn SJ, Osburn BI, Stott JL: Integrated bovine leukosis proviral DNA in T helper and T cytotoxic/suppressor lymphocytes. J Gen Virol. 1991, 72 ( Pt 2): 307-315.Google Scholar
- 221.Yan XJ, Albesiano E, Zanesi N, Yancopoulos S, Sawyer A, Romano E, Petlickovski A, Efremov DG, Croce CM, Chiorazzi N: B cell receptors in TCL1 transgenic mice resemble those of aggressive, treatment-resistant human chronic lymphocytic leukemia. Proc Natl Acad Sci U S A. 2006, 103: 11713-11718. 10.1073/pnas.0604564103.PubMedCentralPubMedGoogle Scholar
- 230.Takahashi M, Tajima S, Takeshima SN, Konnai S, Yin SA, Okada K, Davis WC, Aida Y: Ex vivo survival of peripheral blood mononuclear cells in sheep induced by bovine leukemia virus (BLV) mainly occurs in CD5- B cells that express BLV. Microbes Infect. 2004, 6: 584-595. 10.1016/j.micinf.2004.02.014.PubMedGoogle Scholar
- 241.Silverman LR, Phipps AJ, Montgomery A, Ratner L, Lairmore MD: Human T-cell lymphotropic virus type 1 open reading frame II-encoded p30II is required for in vivo replication: evidence of in vivo reversion. J Virol. 2004, 78: 3837-3845. 10.1128/JVI.78.8.3837-3845.2004.PubMedCentralPubMedGoogle Scholar
- 242.Van den BA, Cleuter Y, Beskorwayne T, Kerkhofs P, Szynal M, Bagnis C, Burny A, Griebel P: CD154 costimulated ovine primary B cells, a cell culture system that supports productive infection by bovine leukemia virus. J Virol. 2001, 75: 1095-1103. 10.1128/JVI.75.3.1095-1103.2001.Google Scholar
- 246.Kettmann R, Deschamps J, Cleuter Y, Couez D, Burny A, Marbaix G: Leukemogenesis by bovine leukemia virus: proviral DNA integration and lack of RNA expression of viral long terminal repeat and 3' proximate cellular sequences. Proc Natl Acad Sci U S A. 1982, 79: 2465-2469. 10.1073/pnas.79.8.2465.PubMedCentralPubMedGoogle Scholar
- 251.Kettmann R, Marbaix G, Cleuter Y, Portetelle D, Mammerickx M, Burny A: Genomic integration of bovine leukemia provirus and lack of viral RNA expression in the target cells of cattle with different responses to BLV infection. Leuk Res. 1980, 4: 509-519. 10.1016/0145-2126(80)90062-4.PubMedGoogle Scholar
- 286.Kabeya H, Ohashi K, Oyunbileg N, Nagaoka Y, Aida Y, Sugimoto C, Yokomizo Y, Onuma M: Up-regulation of tumor necrosis factor alpha mRNA is associated with bovine-leukemia virus (BLV) elimination in the early phase of infection. Vet Immunol Immunopathol. 1999, 68: 255-265. 10.1016/S0165-2427(99)00029-X.PubMedGoogle Scholar
- 290.Usui T, Konnai S, Ohashi K, Onuma M: Interferon-gamma expression associated with suppression of bovine leukemia virus at the early phase of infection in sheep. Vet Immunol Immunopathol. 2006Google Scholar
- 291.Murakami K, Sentsui H, Inoshima Y, Inumaru S: Increase in gammadelta T cells in the blood of cattle persistently infected with bovine leukemia virus following administration of recombinant bovine IFN-gamma. Vet Immunol Immunopathol. 2004, 101: 61-71. 10.1016/j.vetimm.2004.04.016.PubMedGoogle Scholar
- 292.Yakobson B, Brenner J, Ungar-Waron H, Trainin Z: Cellular immune response cytokine expression during the initial stage of bovine leukemia virus (BLV) infection determines the disease progression to persistent lymphocytosis. Comp Immunol Microbiol Infect Dis. 2000, 23: 197-208. 10.1016/S0147-9571(99)00074-0.PubMedGoogle Scholar
- 308.Konnai S, Usui T, Ikeda M, Kohara J, Hirata TI, Okada K, Ohashi K, Onuma M: Tumor necrosis factor-alpha genetic polymorphism may contribute to progression of bovine leukemia virus-infection. Microbes Infect. 2006Google Scholar
- 323.Alcaraz TS, Kerkhofs P, Reichert M, Kettmann R, Willems L: Involvement of glutathione as a mechanism of indirect protection against spontaneous ex vivo apoptosis associated with bovine leukemia virus. Journal of Virology. 2004, 78: 6180-6189. 10.1128/JVI.78.12.6180-6189.2004.PubMedCentralGoogle Scholar
- 325.Dequiedt F, Cantor GH, Hamilton VT, Pritchard SM, Davis WC, Kerkhofs P, Burny A, Kettmann R, Willems L: Bovine leukemia virus-induced persistent lymphocytosis in cattle does not correlate with increased ex vivo survival of B lymphocytes. J Virol. 1999, 73: 1127-1137.PubMedCentralPubMedGoogle Scholar
- 329.Debacq C, Asquith B, Kerkhofs P, Portetelle D, Burny A, Kettmann R, Willems L: Increased cell proliferation, but not reduced cell death, induces lymphocytosis in bovine leukemia virus-infected sheep. Proc Natl Acad Sci U S A. 2002, 99: 10048-10053. 10.1073/pnas.142100999.PubMedCentralPubMedGoogle Scholar
- 335.Debacq C, Gillet N, Asquith B, Sanchez-Alcaraz MT, Florins A, Boxus M, Schwartz-Cornil I, Bonneau M, Jean G, Kerkhofs P, Hay J, Thewis A, Kettmann R, Willems L: Peripheral blood B-cell death compensates for excessive proliferation in lymphoid tissues and maintains homeostasis in bovine leukemia virus-infected sheep. J Virol. 2006, 80: 9710-9719. 10.1128/JVI.01022-06.PubMedCentralPubMedGoogle Scholar
- 336.Asquith B, Debacq C, Florins A, Gillet N, Sanchez Alcaraz MT, Mosley A, Willems L: Quantifying lymphocyte kinetics in vivo using CFSE. Proceedings of the Royal Society of London. 2006, in press:Google Scholar
- 337.Florins A, Gillet N, Asquith B, Debacq C, Jean G, Schwartz-Cornil I, Bonneau M, Burny A, Reichert M, Kettmann R, Willems L: Spleen-Dependent Turnover of CD11b Peripheral Blood B Lymphocytes in Bovine Leukemia Virus-Infected Sheep. J Virol. 2006, 80: 11998-12008. 10.1128/JVI.01447-06.PubMedCentralPubMedGoogle Scholar
- 338.Achachi A, Florins A, Gillet N, Debacq C, Urbain P, Foutsop GM, Vandermeers F, Jasik A, Reichert M, Kerkhofs P, Lagneaux L, Burny A, Kettmann R, Willems L: Valproate activates bovine leukemia virus gene expression, triggers apoptosis, and induces leukemia/lymphoma regression in vivo. Proc Natl Acad Sci U S A. 2005, 102: 10309-10314. 10.1073/pnas.0504248102.PubMedCentralPubMedGoogle Scholar
- 340.Hivin P, Basbous J, Raymond F, Henaff D, Arpin-Andre C, Robert-Hebmann V, Barbeau B, Mesnard JM: The HBZ-SP1 isoform of human T-cell leukemia virus type I represses JunB activity by sequestration into nuclear bodies. Retrovirology. 2007, 4: 14-10.1186/1742-4690-4-14.PubMedCentralPubMedGoogle Scholar
- 348.Insinga A, Monestiroli S, Ronzoni S, Gelmetti V, Marchesi F, Viale A, Altucci L, Nervi C, Minucci S, Pelicci PG: Inhibitors of histone deacetylases induce tumor-selective apoptosis through activation of the death receptor pathway. Nature Medicine. 2005, 11: 71-76. 10.1038/nm1160.PubMedGoogle Scholar
- 349.Nebbioso A, Clarke N, Voltz E, Germain E, Ambrosino C, Bontempo P, Alvarez R, Schiavone EM, Ferrara F, Bresciani F, Weisz A, de Lera AR, Gronemeyer H, Altucci L: Tumor-selective action of HDAC inhibitors involves TRAIL induction in acute myeloid leukemia cells. Nature Medicine. 2005, 11: 77-84. 10.1038/nm1161.PubMedGoogle Scholar
- 352.Saito M, Nakagawa M, Kaseda S, Matsuzaki T, Jonosono M, Eiraku N, Kubota R, Takenouchi N, Nagai M, Furukawa Y, Usuku K, Izumo S, Osame M: Decreased human T lymphotropic virus type I (HTLV-I) provirus load and alteration in T cell phenotype after interferon-alpha therapy for HTLV-I-associated myelopathy/tropical spastic paraparesis. Journal of Infectious Diseases. 2004, 189: 29-40. 10.1086/380101.PubMedGoogle Scholar
- 353.Ikegami M, Umehara F, Ikegami N, Maekawa R, Osame M: Selective matrix metalloproteinase inhibitor, N-biphenyl sulfonyl phenylalanine hydroxamic acid, inhibits the migration of CD4(+) T lymphocytes in patients with HTLV-I-associated myelopathy. Journal of Neuroimmunology. 2002, 127: 134-138. 10.1016/S0165-5728(02)00100-5.PubMedGoogle Scholar
- 356.Taylor GP, Hall SE, Navarrete S, Michie CA, Davis R, Witkover AD, Rossor M, Nowak MA, Rudge P, Matutes E, Bangham CRM, Weber JN: Effect of lamivudine on human T-cell leukemia virus type 1 (HTLV-1) DNA copy number, T-cell phenotype, and anti-tax cytotoxic T-cell frequency in patients with HTLV-1-associated myelopathy. Journal of Virology. 1999, 73: 10289-10295.PubMedCentralPubMedGoogle Scholar
- 357.Taylor GP, Goon P, Furukawa Y, Green H, Barfield A, Mosley A, Nose H, Babiker A, Rudge P, Usuku K, Osame M, Bangham CR, Weber JN: Zidovudine plus lamivudine in Human T-Lymphotropic Virus type-I-associated myelopathy: a randomised trial. Retrovirology. 2006, 3: 63-10.1186/1742-4690-3-63.PubMedCentralPubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.